News Releases

Evofem honored amongst best companies globally for outstanding innovation with first-in-class non-hormonal prescription contraceptive vaginal gel, Phexxi®

Approximately 25 Million Adult Women Covered by Medicaid

High Level of Interest from Clinical Sites Seeking to Participate in EVOGUARD Trial

Launched Phexxi™ (lactic acid, citric acid, potassium bitartrate) in U.S. for Hormone-free Contraception

-- Conference Call Scheduled for 5:00 p.m. ET --